Regarding the ADCS-ADL results from the blarcamesine Phase 2b/3 trial for the treatment of early stage Alzheimer's disease
Those in Group1 are super responders!!!
If you look at the linked graph and table from the Phase 2a trial, then you will see that for the super responders in Group 1, the most important factors are:
Baseline MMSE score of greater than or equal to 20 (this is met by everyone in the Phase 2b/3 trial by the inclusion/exclusion criteria
SIGMAR1 wild type (normal) met by approximately 80% or more of the general population
APOE e3 alleles which should be met by 45% or better of all Alzheimer’s patients and about 75% or more of the total population.
The remaining factor is high mean (arithmetic average over time) plasma concentration of Anavex 2-73 for the Phase 2a trial that was defined as 4ng/ml or greater.
Market Data 
Markets 
AI
